利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

11 条记录 (耗时 0.02 秒)

    Method of chain combination
    1.
    发明授权
    Method of chain combination 失效
    链条组合方法

    公开(公告)号：US4835251A

    公开(公告)日：1989-05-30

    申请号：US877819

    申请日：1986-06-23

    申请人： John P. Burnier ,  Paul D. Johnston

    发明人： John P. Burnier ,  Paul D. Johnston

    IPC分类号： A61K38/22 ,  A61K38/00 ,  A61P15/04 ,  C07K1/02 ,  C07K1/113 ,  C07K14/00 ,  C07K14/575 ,  C07K14/64

    CPC分类号： C07K14/64 ,  A61K38/00 ,  Y10S930/26

    摘要： Production of human relaxin or novel human relaxin analogs by combination of a human relaxin A-chain and B-chain comprises combining the reduced form of the human relaxin A-chain and the reduced form of the human relaxin B-chain in an aqueous medium having a pH of about 7.0 to 12 at room temperature, under conditions that are mildly denaturing for the relaxin B-chain such that the human relaxin or novel human relaxin analog can be formed.

    摘要翻译： 通过人松弛素A链和B链的组合制备人类松弛素或新型人类松弛素类似物包括将还原形式的人松弛素A链和还原形式的人松弛素B链在含水培养基中混合， 在室温下，在对松弛素B链进行轻度变性的条件下，pH约为7.0至12，使得可以形成人松弛素或新型人类松弛素类似物。

    Biologically active polypeptides based on transforming growth factor-.beta.
    5.
    发明授权
    Biologically active polypeptides based on transforming growth factor-.beta. 失效
    基于转化生长因子-β序列和使用方法的生物活性多肽

    公开(公告)号：US5118791A

    公开(公告)日：1992-06-02

    申请号：US714462

    申请日：1991-06-13

    申请人： John P. Burnier ,  George J. Cianciolo

    发明人： John P. Burnier ,  George J. Cianciolo

    IPC分类号： A61K38/00 ,  C07K14/495 ,  C07K16/22

    CPC分类号： C07K16/22 ,  C07K14/495 ,  A61K38/00

    摘要： A polypeptide is provided that excludes (a) a full-length mature TGF-.beta. molecule or precursor TGF-.beta. molecule or deletion variants of mature or precursor TGF-.beta.molecules in which from about 1 to 10 amino acid residues have been delected, (b) a polypeptide of the sequence: Cys-Val-Arg-Gln-Leu-Tyr-Ile-Asp-Phe-Arg-Lys-Asp-Leu-Gly-Trp-Lys, and (c) a polypeptide of the sequence: Arg-Asn -Leu-Glu-Glu-Asn-Cys-Cys-Val-Arg-Pro-Leu-Tyr-Ile-Asp-Phe-Arg-Gln-Asp-Leu, said polypeptide comprising an amino acid sequence that is based on conserved sequences in the family of TGF-.beta. molecules. Such polypeptides are particularly useful therapeutically as immunosuppressive agents when coupled to carrier proteins or crosslinked to form polymers.

    摘要翻译： 提供了多肽，其不包括（a）全长成熟TGF-β分子或前体TGF-β分子或成熟或前体TGF-β分子的缺失变体，其中约1至10个氨基酸残基已被选择（ b）序列的多肽：Cys-Val-Arg-Gln-Leu-Tyr-Ile-Asp-Phe-Arg-Lys-Asp-Leu-Gly-Trp-Lys，和（c）序列多肽： Arg-Asn -Leu-Glu-Glu-Asn-Cys-Cys-Val-Arg-Pro-Leu-Tyr-Ile-Asp-Phe-Arg-Gln-Asp-Leu，所述多肽包含基于 在TGF-β分子家族中的保守序列。 当与载体蛋白偶联或交联以形成聚合物时，这样的多肽在治疗上特别可用作免疫抑制剂。

    Biologically active polypeptides based on transforming growth factor-.beta.
    7.
    发明授权
    Biologically active polypeptides based on transforming growth factor-.beta. 失效
    基于转化生长因子（BETA）序列的生物活性多聚体

    公开(公告)号：US5061786A

    公开(公告)日：1991-10-29

    申请号：US356964

    申请日：1989-05-25

    申请人： John P. Burnier ,  George J. Cianciolo

    发明人： John P. Burnier ,  George J. Cianciolo

    IPC分类号： A61K38/00 ,  C07K14/495 ,  C07K16/22

    CPC分类号： C07K14/495 ,  C07K16/22 ,  A61K38/00 ,  Y10S514/966 ,  Y10S930/12

    摘要： A polypeptide is provided that excludes (a) a full-length mature TGF-.beta. molecule or precursor TGF-.beta. molecule or deletion variants of mature or precursor TGF-.beta. molecules in which from about 1 to 10 amino acid residues have been deleted, (b) a polypeptide of the sequence: Cys-Val-Arg-Gln-Leu-Tyr-Ile-Asp-Phe-Arg-Lys-Asp-Leu-Gly-Trp-Lys, and (c) a polypeptide of the sequence: Arg Asn-Leu-Glu-Glu-Asn-Cys-Cys-Val-Arg-Pro-Leu-Tyr-Ile-Asp-Phe-Arg-Gln-Asp-Leu, said polypeptide comprising an amino acid sequence that is based on conserved sequences in the family of TGF-.beta. molecules. Such polypeptides are particularly useful therapeutically as immunosuppressive agents when coupled to carrier proteins or crosslinked to form polymers.

    摘要翻译： 提供了多肽，其不包括（a）全长成熟TGF-β分子或前体TGF-β分子或其中约1至10个氨基酸残基已被缺失的成熟或前体TGF-β分子的缺失变体（ b）序列的多肽：Cys-Val-Arg-Gln-Leu-Tyr-Ile-Asp-Phe-Arg-Lys-Asp-Leu-Gly-Trp-Lys，和（c）序列多肽： Arg Asn-Leu-Glu-Glu-Asn-Cys-Cys-Val-Arg-Pro-Leu-Tyr-Ile-Asp-Phe-Arg-Gln-As p-Leu，所述多肽包含基于 在TGF-β分子家族中的保守序列。 当与载体蛋白偶联或交联以形成聚合物时，这样的多肽在治疗上特别可用作免疫抑制剂。

    Receptor specific atrial natriuretic peptides
    8.
    发明授权
    Receptor specific atrial natriuretic peptides 有权
    受体特异性心房利钠肽

    公开(公告)号：US06525022B1

    公开(公告)日：2003-02-25

    申请号：US09154390

    申请日：1998-09-16

    申请人： David G. Lowe ,  Brian C. Cunningham ,  David Oare ,  Robert S. McDowell ,  John P. Burnier

    发明人： David G. Lowe ,  Brian C. Cunningham ,  David Oare ,  Robert S. McDowell ,  John P. Burnier

    IPC分类号： A61K3812

    CPC分类号： C07K14/58 ,  A61K38/00

    摘要： Human receptor selective atrial natriuretic factor variants containing various substitutions, especially G16R, show equal potency and binding affinity for the human A-receptor but have decreased affinity for the human clearance or C-receptor. These ANF variants have natriuretic, diuretic and vasorelaxant activity but have increased metabolic stability, making them suitable for treating congestive heart failure, acute kidney failure and renal hypertension.

    摘要翻译： 含有各种取代，特别是G16R的人受体选择性心房利钠因子变体对人A受体显示相同的效力和结合亲和力，但对人清除或C-受体的亲和力降低。 这些ANF变体具有利钠，利尿和血管舒张活性，但具有增加的代谢稳定性，使其适合于治疗充血性心力衰竭，急性肾衰竭和肾性高血压。